Eisai Company, Ltd. Presents New Quality of Life Findings in Patients with Metastatic Breast Cancer From Halaven® (Eribulin) Versus Capecitabine Study at 49th American Society of Clinical Oncology Annual Meeting

Published: Jun 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Tokyo, June 3, 2013 (JCN Newswire) - Eisai Co., Ltd. announced today at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) new findings showing that Halaven(R) (eribulin mesylate, "eribulin") improved overall quality of life (QOL) (Global Health Status and QOL, "GHS/QOL") significantly more than capecitabine over the course of a Phase III study (Study 301) in patients with metastatic breast cancer who had been previously treated with anthracyclines and taxanes.

Help employers find you! Check out all the jobs and post your resume.

Back to news